Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545037 · ClinicalTrials.gov registry record · Phase 2
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
A Phase 2 study of Irritable Bowel Syndrome, sponsored by Bio-K Plus International.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
- 3
- Study locations
NCT01545037 is a Phase 2 study of Irritable Bowel Syndrome that has completed, run by Bio-K Plus International. The registered enrollment target is 117 participants, below the 142-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (18% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT01545037, a Phase 2 study of Irritable Bowel Syndrome, has completed, sponsored by Bio-K Plus International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
Study Locations (3)
California
- Digestive and Liver Disease Specialists A Medical Group. Inc - Garden Grove
- Sprim ALS - San Francisco
- Westlake Medical Research - Westlake Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01545037
The ClinicalTrials.gov registry entry for NCT01545037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (18% lower). The listed sponsor is Bio-K Plus International, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01545037 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01545037 about?
NCT01545037 is a clinical study titled "Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome". The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
What is the current status of trial NCT01545037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2012-07. Estimated completion is 2015-01.
What conditions does trial NCT01545037 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT01545037?
The interventions under investigation include: Placebo (OTHER), L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01545037?
This trial is sponsored by Bio-K Plus International, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01545037 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psyllium in Pediatric IBS
RECRUITING · Phase 2
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
RECRUITING · Phase 2
-
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
ACTIVE NOT RECRUITING · Phase 2
-
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
COMPLETED · Phase 2
-
Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.